[
  {
    "ts": null,
    "headline": "Are Investors Undervaluing Eli Lilly and Company (NYSE:LLY) By 41%?",
    "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share price...",
    "url": "https://finnhub.io/api/news?id=71487c128e71d5d925aaecfbd61c4453e220393281d4bf127ae2bbb09f548627",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735470035,
      "headline": "Are Investors Undervaluing Eli Lilly and Company (NYSE:LLY) By 41%?",
      "id": 132197617,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/1b6847ee48493a5698212be177362a15",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share price...",
      "url": "https://finnhub.io/api/news?id=71487c128e71d5d925aaecfbd61c4453e220393281d4bf127ae2bbb09f548627"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders",
    "summary": "The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.  One billionaire investor whom investors of all sizes follow closely is Philippe Laffont of Coatue Management.  Known for investing in a combination of tech and healthcare stocks, Laffont grew his fund to $26.9 billion at the end of September.",
    "url": "https://finnhub.io/api/news?id=6c0419beb66f6325fd32241a67a470e88e4cc8fefdb287f2e1980802e8ec07a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735468740,
      "headline": "Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders",
      "id": 132195595,
      "image": "https://g.foolcdn.com/editorial/images/802136/investor-looking-for-stocks-getty.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.  One billionaire investor whom investors of all sizes follow closely is Philippe Laffont of Coatue Management.  Known for investing in a combination of tech and healthcare stocks, Laffont grew his fund to $26.9 billion at the end of September.",
      "url": "https://finnhub.io/api/news?id=6c0419beb66f6325fd32241a67a470e88e4cc8fefdb287f2e1980802e8ec07a0"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock a Buy?",
    "summary": "While Novo Nordisk's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well.  While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself \"Ozempic Santa,\" he wasn't taking Ozempic.  Reports indicate he was actually taking Eli Lilly's (NYSE: LLY) weight-loss drug Mounjaro.",
    "url": "https://finnhub.io/api/news?id=ef7e0e4b5b6dcbd647d3a82478ac0d7456b9e94d551a2a89adcd89b53db3b99d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735464900,
      "headline": "Is Eli Lilly Stock a Buy?",
      "id": 132195596,
      "image": "https://g.foolcdn.com/editorial/images/802194/gettyimages-2025836701.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While Novo Nordisk's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well.  While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself \"Ozempic Santa,\" he wasn't taking Ozempic.  Reports indicate he was actually taking Eli Lilly's (NYSE: LLY) weight-loss drug Mounjaro.",
      "url": "https://finnhub.io/api/news?id=ef7e0e4b5b6dcbd647d3a82478ac0d7456b9e94d551a2a89adcd89b53db3b99d"
    }
  }
]